Dr Andy Moore
Dr

Andy Moore

Email: 

Background

Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).

Availability

Dr Andy Moore is:
Not available for supervision
Media expert

Fields of research

Biomedical and Clinical Sciences Cancer genetics Cancer therapy (excl. chemotherapy and radiation therapy) Cardiovascular medicine and haematology Chemotherapy Haematological tumours Haematology Molecular targets Oncology and carcinogenesis Oncology and carcinogenesis not elsewhere classified Paediatrics Solid tumours

Qualifications

  • Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
  • Doctor of Philosophy, University College London

Research interests

  • Acute Myeloid Leukaemia

  • Leukaemia

  • Blood Cancers

  • Paediatric Oncology

  • Childhood Cancer

  • Biobanking

Search Professor Andy Moore’s works on UQ eSpace

91 works between 2007 and 2024
All (91) Journal Article (74) Conference Publication (17)

41 - 60 of 91 works

2018

Journal Article

The genetic basis and cell of origin of mixed phenotype acute leukaemia

Alexander, Thomas B., Gu, Zhaohui, Iacobucci, Ilaria, Dickerson, Kirsten, Choi, John K., Xu, Beisi, Payne-Turner, Debbie, Yoshihara, Hiroki, Loh, Mignon L., Horan, John, Buldini, Barbara, Basso, Giuseppe, Elitzur, Sarah, de Haas, Valerie, Zwaan, C. Michel, Yeoh, Allen, Reinhardt, Dirk, Tomizawa, Daisuke, Kiyokawa, Nobutaka, Lammens, Tim, De Moerloose, Barbara, Catchpoole, Daniel, Hori, Hiroki, Moorman, Anthony, Moore, Andrew S., Hrusak, Ondrej, Meshinchi, Soheil, Orgel, Etan, Devidas, Meenakshi ... Mullighan, Charles G. (2018). The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 562 (7727), 373-379. doi: 10.1038/s41586-018-0436-0

The genetic basis and cell of origin of mixed phenotype acute leukaemia

2018

Journal Article

Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells

Vinci, Mara, Burford, Anna, Molinari, Valeria, Kessler, Ketty, Popov, Sergey, Clarke, Matthew, Taylor, Kathryn R., Pemberton, Helen N., Lord, Christopher J., Gutteridge, Alice, Forshew, Tim, Carvalho, Diana, Marshall, Lynley V., Qin, Elizabeth Y., Ingram, Wendy J., Moore, Andrew S., Ng, Ho-Keung, Trabelsi, Saoussen, H’mida-Ben Brahim, Dorra, Entz-Werle, Natacha, Zacharoulis, Stergios, Vaidya, Sucheta, Mandeville, Henry C., Bridges, Leslie R., Martin, Andrew J., Al-Sarraj, Safa, Chandler, Christopher, Sunol, Mariona, Mora, Jaume ... Jones, Chris (2018). Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 24 (8), 1204-1215. doi: 10.1038/s41591-018-0086-7

Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells

2018

Journal Article

Molecular minimal residual disease monitoring in acute myeloid leukemia: challenges and future directions

Selim, Adrian and Moore, Andrew S (2018). Molecular minimal residual disease monitoring in acute myeloid leukemia: challenges and future directions. The Journal of Molecular Diagnostics, 20 (4), 389-397. doi: 10.1016/j.jmoldx.2018.03.005

Molecular minimal residual disease monitoring in acute myeloid leukemia: challenges and future directions

2018

Journal Article

Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study

Aitken, Joanne F, Youlden, Danny R, Moore, Andrew S, Baade, Peter D, Ward, Leisa J, Thursfield, Vicky J, Valery, Patricia C, Green, Adèle C, Gupta, Sumit and Frazier, A Lindsay (2018). Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study. The Lancet Child and Adolescent Health, 2 (3), 173-179. doi: 10.1016/S2352-4642(18)30023-3

Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study

2018

Journal Article

The MLL recombinome of acute leukemias in 2017

Meyer, C, Burmeister, T, Gröger, D, Tsaur, G, Fechina, L, Renneville, A, Sutton, R, Venn, N C, Emerenciano, M, Pombo-de-Oliveira, M S, Barbieri Blunck, C, Almeida Lopes, B, Zuna, J, Trka, J, Ballerini, P, Lapillonne, H, De Braekeleer, M, Cazzaniga, G, Corral Abascal, L, van der Velden, V H J, Delabesse, E, Park, T S, Oh, S H, Silva, M L M, Lund-Aho, T, Juvonen, V, Moore, A S, Heidenreich, O, Vormoor, J ... Marschalek, R (2018). The MLL recombinome of acute leukemias in 2017. Leukemia, 32 (2), 273-284. doi: 10.1038/leu.2017.213

The MLL recombinome of acute leukemias in 2017

2018

Journal Article

The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion

Burford, Anna, Mackay, Alan, Popov, Sergey, Vinci, Maria, Carvalho, Diana, Clarke, Matthew, Izquierdo, Elisa, Avery, Aimee, Jacques, Thomas S., Ingram, Wendy J., Moore, Andrew S., Frawley, Kieran, Hassall, Timothy E., Robertson, Thomas and Jones, Chris (2018). The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion. Scientific Reports, 8 (1) 1032, 1-10. doi: 10.1038/s41598-018-19389-9

The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion

2018

Conference Publication

The molecular pathology of infant gliomas

Clarke, M., Jones, D. T. W., Carvalho, D., Mackay, A., Izquierdo, E., Hargrave, D., Moore, A. S., Popov, S., Jacques, T. and Jones, C. (2018). The molecular pathology of infant gliomas. 119th Meeting of the British-Neuropathological-Society (BNS) / Epilepsy Neuropathology Symposium, London England, Feb 28-Mar 02 2018. Hoboken, NJ United States: Wiley.

The molecular pathology of infant gliomas

2018

Conference Publication

The Molecular Pathology of Infant Gliomas

Clarke, M. T., Jones, D., Carvalho, D. M., Mackay, A., Izquierdo, E., Hargrave, D., Moore, A. S., Popov, S., Jacques, T. S. and Jones, C. (2018). The Molecular Pathology of Infant Gliomas. Winter Meeting on Epigenetics - Understanding Disease and Guiding Therapies / Joint Meeting of the Royal-Society-of-Medicine / 209th Scientific Meeting of the Pathological-Society-of-Great-Britain-and-Ireland, Marylebone England, 25-26 January 2018. Hoboken, NJ United States: Wiley.

The Molecular Pathology of Infant Gliomas

2018

Conference Publication

Quantitative analysis of MLL fusion transcripts by droplet digital PCR to monitor minimal residual disease in MLL-rearranged acute myeloid leukemia

Afrin, Sadia, Zhang, Christine R. C., Meyer, Claus, Maybury, Mellissa, Pham, Thy, Venn, Nicola, Trahair, Toby N., Sutton, Rosemary, Marschalek, Rolf, Fink, Lynn and Moore, Andrew S. (2018). Quantitative analysis of MLL fusion transcripts by droplet digital PCR to monitor minimal residual disease in MLL-rearranged acute myeloid leukemia. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA USA, 1-4 December 2018. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2018-99-117761

Quantitative analysis of MLL fusion transcripts by droplet digital PCR to monitor minimal residual disease in MLL-rearranged acute myeloid leukemia

2018

Conference Publication

Aberrant splicing of KMT2A as a potential molecular MRD marker in cytogenetically-normal AML

Zhang, Christine R. C., Afrin, Sadia, Maybury, Mellissa, Pham, Thy, Fink, Lynn and Moore, Andrew S. (2018). Aberrant splicing of KMT2A as a potential molecular MRD marker in cytogenetically-normal AML. 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA USA, 1-4 December 2018. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2018-99-117759

Aberrant splicing of KMT2A as a potential molecular MRD marker in cytogenetically-normal AML

2017

Journal Article

Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours

Izquierdo, Elisa, Yuan, Lina, George, Sally, Hubank, Michael, Jones, Chris, Proszek, Paula, Shipley, Janet, Gatz, Susanne A., Stinson, Caedyn, Moore, Andrew S., Clifford, Steven C., Hicks, Debbie, Lindsey, Janet C., Hill, Rebecca M., Jacques, Thomas S., Chalker, Jane, Thway, Khin, O'Connor, Simon, Marshall, Lynley, Moreno, Lucas, Pearson, Andrew, Chesler, Louis, Walker, Brian A. and De Castro, David Gonzalez (2017). Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 8 (67), 112036-112050. doi: 10.18632/oncotarget.23000

Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours

2017

Journal Article

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

Heatley, Susan L., Sadras, Teresa, Kok, Chung H., Nievergall, Eva, Quek, Kelly, Dang, Phuong, McClure, Barbara, Venn, Nicola, Moore, Sarah, Suttle, Jeffrey, Law, Tamara, Ng, Anthea, Muskovic, Walter, Norris, Murray D., Revesz, Tamas, Osborn, Michael, Moore, Andrew S., Suppiah, Ram, Fraser, Chris, Alvaro, Frank, Hughes, Timothy P., Mullighan, Charles G., Marshall, Glenn M., Pozza, Luciano Dalla, Yeung, David T., Sutton, Rosemary and White, Deborah L. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 102 (12), 490-493. doi: 10.3324/haematol.2016.162925

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

2017

Journal Article

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions

Sadras, Teresa, Heatley, Susan L, Kok, Chung H., Dang, Phuong, Galbraith, Kate M., McClure, Barbara J., Muskovic, Walter, Venn, Nicola C., Moore, Sarah, Osborn, Michael, Revesz, Tamas, Moore, Andrew S., Hughes, Timothy P., Yeung, David, Sutton, Rosemary and White, Deborah L. (2017). Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 408, 92-101. doi: 10.1016/j.canlet.2017.08.034

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions

2017

Journal Article

Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma

Mackay, Alan, Burford, Anna, Carvalho, Diana, Izquierdo, Elisa, Fazal-Salom, Janat, Taylor, Kathryn R., Bjerke, Lynn, Clarke, Matthew, Vinci, Mara, Nandhabalan, Meera, Temelso, Sara, Popov, Sergey, Molinari, Valeria, Raman, Pichai, Waanders, Angela J., Han, Harry J., Gupta, Saumya, Marshall, Lynley, Zacharoulis, Stergios, Vaidya, Sucheta, Mandeville, Henry C., Bridges, Leslie R., Martin, Andrew J., Al-Sarraj, Safa, Chandler, Christopher, Ng, Ho-Keung, Li, Xingang, Mu, Kun, Trabelsi, Saoussen ... Jones, Chris (2017). Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell, 32 (4), 520-+. doi: 10.1016/j.ccell.2017.08.017

Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma

2017

Journal Article

Erratum to: Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? (Cancer Chemotherapy and Pharmacology, (2017), 80, 1, (15-25), 10.1007/s00280-017-3309-6)

Kunarajah, Kuhan, Hennig, Stefanie, Norris, Ross L. G., Lobb, Michael, Charles, Bruce G., Pinkerton, Ross and Moore, Andrew S. (2017). Erratum to: Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? (Cancer Chemotherapy and Pharmacology, (2017), 80, 1, (15-25), 10.1007/s00280-017-3309-6). Cancer Chemotherapy and Pharmacology, 80 (1), 27-28. doi: 10.1007/s00280-017-3338-1

Erratum to: Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? (Cancer Chemotherapy and Pharmacology, (2017), 80, 1, (15-25), 10.1007/s00280-017-3309-6)

2017

Journal Article

Intertumoral heterogeneity within medulloblastoma subgroups

Cavalli, Florence M. G., Remke, Marc, Rampasek, Ladislav, Peacock, John, Shih, David J. H., Luu, Betty, Garzia, Livia, Torchia, Jonathon, Nor, Carolina, Morrissy, A. Sorana, Agnihotri, Sameer, Thompson, Yuan Yao, Kuzan-Fischer, Claudia M., Farooq, Hamza, Isaev, Karen, Daniels, Craig, Cho, Byung-Kyu, Kim, Seung-Kim, Wang, Kyu-Chang, Lee, Ji Yeoun, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Vasiljevic, Alexandre, Faure-Conter, Cecile, Jouvet, Anne, Giannini, Caterina, Nageswara Rao, Anulya A., Li, Kay Ka Wai, Ng, Ho-Keung ... Taylor, Michael D. (2017). Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 31 (6), 737-754.e6. doi: 10.1016/j.ccell.2017.05.005

Intertumoral heterogeneity within medulloblastoma subgroups

2017

Journal Article

Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?

Kunarajah, Kuhan, Hennig, Stefanie, Norris, Ross L. G., Lobb, Michael, Charles, Bruce G., Pinkerton, Ross and Moore, Andrew S. (2017). Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?. Cancer Chemotherapy and Pharmacology, 80 (1), 15-25. doi: 10.1007/s00280-017-3309-6

Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?

2017

Journal Article

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia

Charmsaz, S., Al-Ejeh, F., Yeadon, T. M., Miller, K. J., Smith, F. M., Stringer, B. W., Moore, A. S., Lee, F.-T., Cooper, L. T., Stylianou, C., Yarranton, G. T., Woronicz, J., Scott, A. M., Lackmann, M. and Boyd, A. W. (2017). EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia, 31 (8), 1779-1787. doi: 10.1038/leu.2016.371

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia

2016

Journal Article

Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors

Torchia, Jonathon, Golbourn, Brian, Feng, Shengrui, Ho, King Ching, Sin-Chan, Patrick, Vasiljevic, Alexandre, Norman, Joseph D., Guilhamon, Paul, Garzia, Livia, Agamez, Natalia R., Lu, Mei, Chan, Tiffany S., Picard, Daniel, de Antonellis, Pasqualino, Khuong-Quang, Dong-Anh, Planello, Aline C., Zeller, Constanze, Barsyte-Lovejoy, Dalia, Lafay-Cousin, Lucie, Letourneau, Louis, Bourgey, Mathieu, Yu, Man, Gendoo, Deena M. A., Dzamba, Misko, Barszczyk, Mark, Medina, Tiago, Riemenschneider, Alexandra N., Morrissy, A. Sorana, Ra, Young-Shin ... Huang, Annie (2016). Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell, 30 (6), 891-908. doi: 10.1016/j.ccell.2016.11.003

Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors

2016

Journal Article

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D. and Vormoor, J. (2016). A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood and Cancer, 64 (6) e26351, e26351. doi: 10.1002/pbc.26351

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Current funding

  • 2023 - 2026
    Life and health after childhood cancer: a national data linkage cohort study (Cancer Australia grant led by The University of Sydney)
    University of Sydney
    Open grant

Past funding

  • 2021 - 2024
    The Queensland Children's Tumour Bank
    The Children's Hospital Foundation
    Open grant
  • 2020 - 2021
    Biobank Network
    Australian and New Zealand Children's Haematology/Oncology Group
    Open grant
  • 2017 - 2020
    Circular RNAs as Trojan Horses of Oncogenesis (RSNCRT grant led by Flinders University)
    Flinders University
    Open grant
  • 2017 - 2019
    Zero Childhood Cancer
    Childrens Cancer Institute Australia
    Open grant
  • 2017
    Improving the detection of residual disease in childhood acute myeloid leukaemia
    The Children's Hospital Foundation
    Open grant
  • 2016 - 2019
    Personalised disease monitoring for improved outcomes in childhood acute myeloid leukaemia
    The Kid's Cancer Project
    Open grant
  • 2016 - 2017
    Personalised disease monitoring to improve treatment of childhood acute myeloid leukaemia
    The Children's Hospital Foundation
    Open grant
  • 2015 - 2016
    Identification of residual disease and novel therapeutic targets in acute myeloid leukaemia (AML)
    The Kid's Cancer Project
    Open grant
  • 2015 - 2016
    Advancing childhood brain tumour research through the Queensland Children's Tumour Bank
    Brainchild Foundation
    Open grant
  • 2015 - 2016
    The impact of re-induction chemotherapy and minimal residual disease on allogeneic haematopoietic stem cell transplantation outcomes for children with acute myeloid leukaemia in second remission.
    Australian and New Zealand Children's Haematology/Oncology Group
    Open grant
  • 2014
    The preclinical development of CBL137 in paediatric AML
    Cancer Bequest Fund
    Open grant
  • 2014 - 2016
    Cell-cycle checkpoint signalling as a novel therapeutic target in paediatric acute myeloid leukaemia (AML)
    Oncology Children's Foundation
    Open grant
  • 2014 - 2017
    The Watts Trust Estate funds for paediatric leukaemia research
    Children's Health Queensland Hospital and Health Service - Oncology Service Group
    Open grant
  • 2014
    Identification of novel therapeutic strategies for childhood acute myeloid leukaemia through integrated genomic and phospho-proteomic analyses
    UQ Early Career Researcher
    Open grant
  • 2013 - 2014
    The Kid's Cancer Project
    Research Donation Generic
    Open grant
  • 2013 - 2018
    The Queensland Children's Tumour Bank - Helping Develop Better Approaches for Treating Childhood Cancers
    Research Donation Generic
    Open grant
  • 2013 - 2014
    Maximising the use of donated tumour tissue from Queensland children for research aimed at improving the diagnosis and treatment of paediatric brain tumours
    Brainchild Foundation
    Open grant
  • 2013 - 2016
    The evaluation of MEK inhibition as a therapeutic strategy for childhood acute myeloid leukaemia
    Children's Health Foundation Queensland
    Open grant
  • 2013 - 2014
    Aminopeptidase inhibition as a therapeutic strategy for childhood acute myeloid leukaemia (I L Thompson Research Fellowship)
    IL Thompson Research Fellowship
    Open grant
  • 2012 - 2013
    The preclinical development of Tosedostat for the treatment of childhood acute myeloid leukaemia
    UQ New Staff Research Start-Up Fund
    Open grant
  • 2012 - 2014
    The role Survivin and XIAP (X-linked inhibitor of apoptosis protein) as biomarkers and therapeutic targets in paediatric acute myeloid leukaemia
    Pfizer Australia Pty Limited
    Open grant
  • 2012 - 2016
    A study to assess the mechanisms of cell death in acute myeloid leukaemia
    Children's Health Foundation Queensland
    Open grant
  • 2012 - 2016
    NHMRC Early Career Fellowship (Australian Health Professional): The role Survivin and XIAP as biomarkers and therapeutic targets in paediatric acute myeloid leukaemia
    NHMRC Training (Postdoctoral) Fellowship
    Open grant
  • 2012 - 2013
    The role Survivin and XIAP (X-linked inhibitor of apoptosis protein) as biomarkers and therapeutic targets in paediatric acute myeloid leukaemia
    ANZ Executors and Trustees' Company Ltd
    Open grant
  • 2007 - 2021
    Queensland Children's Tumour Bank
    Royal Children's Hospital Foundation
    Open grant

Availability

Dr Andy Moore is:
Not available for supervision

Supervision history

Completed supervision

Enquiries

Contact Dr Andy Moore directly for media enquiries about:

  • Childhood Cancer
  • Childhood Leukaemia

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au